📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sanofi India FY25 PBT Rises 1% Amid Transformation; Proposes INR 123 Dividend
Sanofi India reported a 1% increase in Profit Before Tax for FY2025, navigating a significant business transformation including the demerger of its consumer health business. Domestic sales remained flat at INR 1,511 crores, though the core diabetes franchise showed strong momentum with 6% annual growth and 11% growth in Q4. The company achieved a 17% reduction in operating expenses through efficiency measures and partnership models. A total dividend of INR 123 per share has been proposed, representing a 5% increase over the previous year.
Key Highlights
Diabetes franchise grew 6% in FY25, with Q4 growth accelerating to 11%
Lantus maintained market leadership with a 31% share in the basal insulin segment
Operating expenses were reduced by 17% through business model modernization
Proposed total dividend of INR 123 per share for the year, up 5% from 2024
Domestic net sales stood at INR 1,511 crores, while exports declined due to the Ankleshwar site divestment
💼 Action for Investors
Investors should monitor the stabilization of the new partnership model and the growth of the insulin portfolio. The significant reduction in operating costs and consistent dividend payout remain key positives for long-term holders.
Sanofi India FY25 Net Sales Up 1%, Proposes ₹123 Dividend Amid Business Transformation
Sanofi India Limited (SIL) has completed a pivotal business transformation in 2025, shifting focus toward its Diabetes franchise and a partnership model for legacy brands. While FY25 total income fell 9% to ₹18,571 million due to lower other operating income, net sales grew 1% to ₹15,115 million and Profit Before Tax (PBT) rose 1% to ₹4,720 million. The company achieved a significant 17% reduction in operating expenses through structural efficiencies. A dividend of ₹123 per share has been proposed, marking a 5% increase from the previous year.
Key Highlights
FY25 Net Sales reached ₹15,115 million, a 1% increase, while PBT before exceptional items rose 1% to ₹4,720 million.
Operating expenses were slashed by 17% in FY25 to ₹4,489 million, driven by employee cost and OPEX efficiencies.
The Diabetes franchise maintained a 31% market share with a 6% volume acceleration and double-digit growth in Toujeo.
Proposed dividend for 2025 is ₹123 per share, up from ₹117 in 2024, representing an 87% payout ratio.
Q4 2025 performance was softer with PBT declining 27% to ₹830 million compared to Q4 2024.
💼 Action for Investors
Investors should view the successful cost optimization and the 5% dividend hike as signs of financial discipline during a major strategic pivot. Monitor the scaling of the new partnership model for legacy brands and the growth of the high-margin insulin portfolio in upcoming quarters.
Sanofi Consumer Healthcare Q4 Profit Jumps 50% to ₹665 MN; ₹75 Dividend Declared
Sanofi Consumer Healthcare India (SCHIL) reported a robust Q4 performance with revenue growing 47% YoY to ₹2,510 million and net profit surging 50% to ₹665 million. For the full year 2025, the company achieved a 21% revenue growth and a 33% increase in PAT, reaching ₹2,401 million. The board has recommended a substantial dividend of ₹75 per share, reflecting strong cash generation. Growth was primarily driven by a 23% rise in domestic sales and the successful relaunch of recalled products.
Key Highlights
Q4 Revenue grew 47% YoY to ₹2,510 million, while Net Profit rose 50% to ₹665 million.
Full-year FY25 PAT increased by 33% to ₹2,401 million on total revenue of ₹8,784 million.
Declared a significant dividend of ₹75 per share for the financial year ended December 31, 2025.
Domestic sales grew by 23% in Q4, supported by brand relaunches and core portfolio strength.
Export sales for Q4 grew 9.3x and full-year exports grew 158%, albeit from a low base.
💼 Action for Investors
The strong double-digit growth and high dividend payout indicate successful post-demerger stabilization and operational efficiency. Investors may consider this a positive signal for long-term value in the consumer healthcare space, given the strength of brands like Combiflam and Allegra.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹240 Cr; Recommends ₹75 Dividend
Sanofi Consumer Healthcare India reported a strong financial performance for the year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year surged by 32.6% to ₹2,401 million, driven by robust operational performance and higher other income. The Board has recommended a substantial final dividend of ₹75 per equity share, highlighting strong cash flow generation. Quarterly growth was even more pronounced, with Q4 revenue increasing 47% year-on-year to ₹2,510 million.
Key Highlights
Full-year FY25 revenue increased 21.2% to ₹8,784 million from ₹7,245 million in FY24.
Net profit for FY25 rose to ₹2,401 million, up from ₹1,810 million in the previous year.
Board recommended a final dividend of ₹75 per equity share (750% of face value).
Earnings Per Share (EPS) for FY25 improved significantly to ₹104.27 from ₹78.59.
Q4 FY25 net profit stood at ₹665 million, a 50% increase compared to ₹443 million in Q4 FY24.
💼 Action for Investors
Investors should view these results positively given the strong double-digit growth in both top-line and bottom-line, coupled with a high dividend payout. The stock remains attractive for those seeking a combination of growth in the consumer healthcare space and high yield.
Sanofi Consumer Healthcare Recommends Rs 75 Dividend; FY25 Net Profit Rises 33%
Sanofi Consumer Healthcare India has recommended a final dividend of Rs. 75 per share for the financial year ended December 31, 2025. The company reported a strong financial performance with annual revenue growing 21% to Rs. 8,784 million. Net profit for the full year increased significantly by 33% to Rs. 2,401 million compared to the previous year. The quarterly performance was also robust, with Q4 profit rising to Rs. 665 million from Rs. 443 million year-on-year.
Key Highlights
Recommended a final dividend of Rs. 75 per equity share of face value Rs. 10.
Annual Revenue from Operations grew 21.2% YoY to Rs. 8,784 million in FY25.
Net Profit for the full year surged 32.7% to Rs. 2,401 million from Rs. 1,810 million.
Earnings Per Share (EPS) increased to Rs. 104.27 from Rs. 78.59 in the previous year.
Q4 FY25 revenue stood at Rs. 2,510 million, a 47% increase over Q4 FY24.
💼 Action for Investors
Investors should note the strong growth trajectory and the substantial dividend payout which reflects robust cash flows. The stock is likely to be viewed favorably by both growth and income-seeking investors due to the earnings outperformance.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹2,401 Mn; ₹75/Share Dividend Declared
Sanofi Consumer Healthcare India reported a strong performance for the financial year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year increased significantly by 32.6% to ₹2,401 million, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹75 per share, reflecting a high payout ratio and strong cash position. Quarterly performance was also robust, with Q4 revenue up 47% year-on-year to ₹2,510 million.
Key Highlights
Full-year FY25 Revenue from Operations rose 21.2% YoY to ₹8,784 million versus ₹7,245 million.
Net Profit for FY25 increased to ₹2,401 million from ₹1,810 million in the previous year.
Recommended a final dividend of ₹75 per equity share of face value ₹10 for the financial year.
Q4 FY25 Net Profit grew 50% YoY to ₹665 million compared to ₹443 million in Q4 FY24.
Earnings Per Share (EPS) improved significantly to ₹104.27 for FY25 from ₹78.59 in FY24.
💼 Action for Investors
Investors should react positively to the strong double-digit growth in both revenue and profitability alongside a very generous dividend payout. The company's transition and focus on consumer healthcare appear to be yielding high margins and robust cash flows.
Sanofi India FY25 Profit at ₹3,267M; Total Dividend of ₹123 Per Share Declared
Sanofi India reported a total revenue of ₹18,374 million for FY25, down from ₹20,132 million in FY24. Despite the revenue decline, Profit Before Tax from continuing operations improved slightly to ₹4,447 million compared to ₹4,314 million in the previous year. The company has recommended a final dividend of ₹48 per share, which, combined with the interim dividend, brings the total FY25 payout to ₹123 per share. Additionally, the board announced key leadership changes, including the appointment of Ms. Sudipta Chakraborty as Whole-time Director.
Key Highlights
Total dividend for FY25 stands at ₹123 per equity share (Final ₹48 + Interim ₹75)
FY25 Revenue from Operations decreased to ₹18,374 million from ₹20,132 million in FY24
Profit Before Tax from continuing operations rose to ₹4,447 million versus ₹4,314 million YoY
Ms. Sudipta Chakraborty appointed as Whole-time Director for a 3-year term effective March 1, 2026
Mrs. Rajani Kesari appointed as Independent Director for a 5-year term effective April 1, 2026
💼 Action for Investors
Investors should note the strong dividend yield provided by the ₹123 total payout. While revenue from continuing operations has seen some pressure, the improvement in PBT and the induction of experienced leadership in legal and finance roles are positive signs for governance and strategy.
Sanofi India FY25 Profit at ₹3,267M; Total Dividend Recommended at ₹123 Per Share
Sanofi India reported a profit of ₹3,267 million for the financial year ended December 31, 2025, compared to ₹4,135 million in FY24, which included gains from discontinued operations. Revenue from operations for FY25 declined to ₹18,374 million from ₹20,132 million in the previous year. The Board has recommended a final dividend of ₹48 per share, which, combined with the interim dividend, brings the total payout for the year to ₹123 per share. Significant management changes were also announced, including the appointment of a new Whole-time Director and an Independent Director.
Key Highlights
Total dividend for FY25 stands at ₹123 per share, including a newly recommended final dividend of ₹48.
Revenue from operations for FY25 decreased by 8.7% to ₹18,374 million from ₹20,132 million in FY24.
Profit from continuing operations for FY25 saw a slight increase to ₹3,267 million from ₹3,137 million in FY24.
Ms. Sudipta Chakraborty appointed as Whole-time Director for 3 years effective March 1, 2026.
Mrs. Rajani Kesari appointed as Independent Director for a 5-year term starting April 1, 2026.
💼 Action for Investors
Investors should value the consistent high dividend payout which offers a strong yield. While revenue has dipped, the stability in profits from continuing operations and the induction of experienced leadership in legal and finance roles are positive for long-term governance.
Sanofi India Declares ₹123 Total Dividend for FY25; FY25 Continuing Profit Rises to ₹3,267 Million
Sanofi India has recommended a final dividend of ₹48 per share, bringing the total dividend for FY25 to a substantial ₹123 per share. The company reported a 4.1% growth in profit from continuing operations to ₹3,267 million for the full year 2025, despite a decline in annual revenue to ₹18,374 million. Significant leadership changes were announced, including the appointment of Mrs. Rajani Kesari as an Independent Director and Ms. Sudipta Chakraborty as a Whole-time Director. While Q4 revenue saw a year-on-year decline, the high dividend payout remains a key highlight for shareholders.
Key Highlights
Total dividend of ₹123 per share for FY25, including a final dividend of ₹48 and an interim of ₹75.
Profit from continuing operations grew to ₹3,267 million in FY25 from ₹3,137 million in FY24.
Annual revenue from operations for FY25 stood at ₹18,374 million, compared to ₹20,132 million in FY24.
Appointment of Mrs. Rajani Kesari (former CFO of Nayara Energy) as Independent Director for a 5-year term.
Q4 FY25 profit after tax stood at ₹617 million, down from ₹913 million in the same quarter last year.
💼 Action for Investors
Investors should view the high dividend payout as a sign of strong cash flow and commitment to shareholder returns. While revenue growth is currently soft, the steady profit from continuing operations and professional leadership additions support a long-term hold strategy.
Sanofi India Recommends Rs 48 Final Dividend; Total FY25 Dividend Reaches Rs 123 Per Share
Sanofi India has recommended a final dividend of Rs 48 per equity share for the financial year ended December 31, 2025. When combined with the interim dividend of Rs 75 declared in October 2025, the total dividend for the year stands at Rs 123 per share. Financially, the company reported a profit from continuing operations of Rs 3,267 million for FY25, up from Rs 3,137 million in FY24, despite a decline in total revenue. The board also approved significant leadership changes, including the appointment of a new Whole-time Director and an Independent Director.
Key Highlights
Recommended a final dividend of Rs 48 per share, bringing the total FY25 payout to Rs 123 per share
Profit from continuing operations increased to Rs 3,267 million in FY25 from Rs 3,137 million in FY24
Annual revenue from operations declined to Rs 18,374 million compared to Rs 20,132 million in the previous year
Appointed Ms. Sudipta Chakraborty as Whole-time Director for a 3-year term effective March 1, 2026
Mrs. Rajani Kesari appointed as an Independent Director for a 5-year term starting April 1, 2026
💼 Action for Investors
Investors should benefit from the substantial dividend payout which reflects strong cash reserves. While the revenue decline needs monitoring, the growth in profit from continuing operations and high yield make it attractive for income-seeking portfolios.
Sanofi India FY25 Net Profit at ₹3,267 Mn; Total Dividend Declared at ₹123 Per Share
Sanofi India reported a total net profit of ₹3,267 million for the financial year ended December 31, 2025, a decrease from ₹4,135 million in FY24 which included discontinued operations. Revenue from continuing operations for the full year stood at ₹18,374 million, down from ₹20,132 million in the previous year. The Board has recommended a final dividend of ₹48 per share, which, combined with the interim dividend, brings the total payout to ₹123 per share for 2025. Key management changes were also announced, including the appointment of Ms. Sudipta Chakraborty as a Whole-time Director effective March 2026.
Key Highlights
Recommended a final dividend of ₹48 per share, resulting in a total annual dividend of ₹123 per share.
FY25 Revenue from continuing operations declined to ₹18,374 million from ₹20,132 million in FY24.
Profit before tax from continuing operations for FY25 rose slightly to ₹4,447 million versus ₹4,314 million in FY24.
Total Net Profit for FY25 was ₹3,267 million, compared to ₹4,135 million in FY24 which included ₹998 million from discontinued operations.
Appointed Ms. Sudipta Chakraborty as Whole-time Director and Mrs. Rajani Kesari as Independent Director.
💼 Action for Investors
Investors should note the high dividend payout which remains a key attraction for the stock despite the decline in headline revenue. Monitor the impact of the management transition and the performance of the core continuing operations in upcoming quarters.
Sanofi India Shareholders Approve Appointment of Deepak Arora as Managing Director
Sanofi India Limited has announced the successful passage of two ordinary resolutions via postal ballot regarding the appointment of Mr. Deepak Arora. The resolution to appoint him as a Director was passed with an overwhelming 99.84% majority. His appointment as Managing Director also received approval with 94.70% of votes in favor, despite some resistance from public institutions where 17.53% voted against. This leadership transition is now formalized following the conclusion of the remote e-voting process on December 17, 2025.
Key Highlights
Mr. Deepak Arora's appointment as Director approved with 99.84% votes in favor (19,946,099 votes).
Appointment as Managing Director passed with 94.70% majority (18,918,505 votes).
Public Institutions showed 17.53% dissent (against votes) specifically for the Managing Director resolution.
Total votes polled were 19,977,363, representing 86.74% of the total outstanding shares.
The voting results were finalized and reported by the Scrutinizer on December 18, 2025.
💼 Action for Investors
Investors should view this as a completion of a key leadership transition, ensuring management continuity for the pharmaceutical major. While the resolutions passed comfortably, the institutional dissent regarding the MD appointment suggests investors should keep an eye on future governance and strategic execution under the new leadership.